NCT00441922 - Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Docetaxel

Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

DRUG

Vinorelbine

Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

Trial Locations (10)

University General Hospital of Alexandroupolis, Department of Medical Oncology, Alexandroupoli

401 Military Hospital of Athens, Athens

Air Forces Military Hospital of Athens, Athens

IASO General Hospital of Athens, 1st Department of Medical Oncology, Athens

Laikon General Hospital, Medical Oncology Unit, Propedeutic Department of Internal Medicine, Athens

Sismanogleio General Hospital, 1st, 2nd Department of Pulmonary Diseases, Athens

Sotiria General Hospital, 1st, 3rd, 8th Department of Pulmonary Diseases, Athens

State General Hospital of Larissa, Department of Medical Oncology, Larissa

Metaxa's Anticancer Hospital of Piraeus, 1st Department of Medical Oncology, Piraeus

Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki